Coeurative is developing a pharmaceutical management strategy for Coronary Artery Disease, and its main symptom complex, known as Angina Pectoris. Millions of patients suffer from a syndrome known as angina pectoris, symptoms that signal that the heart is not getting the oxygen-rich blood that it needs to function.
Coeurative is harnessing a cellular response to a deficiency in blood and oxygen that can open a coronary artery more effectively and more selectively than currently available vasodilators. We are pioneering a fundamentally different approach to coronary artery disease to restore proper blood flow and reclaim cardiovascular health.
Coeurative aims to bring relief to patients with angina pectoris, with a focus on the patients that suffer from INOCA (Ischemia with Non-Obstructive Coronary Arteries) and refractory angina pectoris, using a novel small molecule with a dual mechanism.
This is more than pharmaceutical development. This is a commitment to transforming how we treat heart disease by giving patients their lives back.
First-in-Class Innovation
CR-0305 has the potential to deliver both immediate relief and long-term vascular benefits through proprietary dual-mechanism approach
In a human coronary artery study performed ex vivo, CR-0305 demonstrated greater vasodilatory potency than isosorbide mononitrate, with reported EC50 values of
3 µM and 67 µM, respectively.
CR-0305 development addresses the gap in care of refractory angina and INOCA (ischemia with non-obstructive coronary arteries)
Market Opportunity
11 million Americans living with angina pectoris
21% still experience monthly attacks despite medical therapy
$16B+ global market opportunity by 2029
17% annual mortality rate in refractory patients
Click here to link to an introductory slide deck describing Coeurative, Inc. and its lead compound.
